MedTrace Logo

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

NCT04999527 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-07-19

No results posted yet for this study

Summary

This Phase 1 study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult healthy volunteers.

Conditions

  • Healthy Volunteer

Interventions

DRUG

DISC-0974

DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose

DRUG

Placebo

Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose

Sponsors & Collaborators

  • Disc Medicine, Inc

    lead INDUSTRY

Principal Investigators

  • William Savage, MD, PhD · Disc Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999527 on ClinicalTrials.gov